Latest News, Grants & Research Reports
Read our latest news, blog posts and research updates right here
![Public update on COVID-19 from Neuroblastoma UK and Solving Kids' Cancer](https://images.squarespace-cdn.com/content/v1/5630f90ee4b032072583da6d/1584448361176-D3BYNYEURLUIDXBUZX0P/Caronavirus.jpg)
Public update on COVID-19 from Neuroblastoma UK and Solving Kids' Cancer
We understand that some families are concerned about COVID-19 / coronavirus.
Neuroblastoma UK and Solving Kids’ Cancer will be working together to ensure that the neuroblastoma community is provided with as much timely and reliable information as possible.
![SIOPEN High-Risk Neuroblastoma Clinical Trial 2 to open in the UK in 2021](https://images.squarespace-cdn.com/content/v1/5630f90ee4b032072583da6d/1589889387675-91RP96GGD1MHWANWMXUK/image-asset.jpeg)
SIOPEN High-Risk Neuroblastoma Clinical Trial 2 to open in the UK in 2021
Neuroblastoma UK with Solving Kids’ Cancer has awarded a grant of £609,762.40 to enable the SIOPEN High-Risk Neuroblastoma Clinical Trial 2 (HR-NBL2) to open in the UK. The trial is anticipated to open in early 2021.
This Phase 3 clinical trial will offer children in the UK, with a diagnosis of high-risk neuroblastoma, to have the same opportunities as children across Europe and take part in this pan-European study, enabling a series of important randomised questions to be answered within the overall framework of the trial.
![Press release: Charities fund new clinical trial to help children with cancer](https://images.squarespace-cdn.com/content/v1/5630f90ee4b032072583da6d/1589887674757-SPN90K6P2L86VDTXGTEF/image-asset.jpeg)
Press release: Charities fund new clinical trial to help children with cancer
Neuroblastoma UK and Solving Kids Cancer have awarded a grant to enable the SIOPEN High-Risk Neuroblastoma Clinical Trial 2 (HR-NBL2) to open in the UK, it is anticipated to open in early 2021.
This Phase 3 clinical trial will offer children in the UK, with a diagnosis of high-risk neuroblastoma, to have the same opportunities as children across Europe and take part in this pan-European study.